Cited by 3,634PARP inhibition in cancer therapyBRCA gene mutations in cancerAdvanced Breast Cancer Therapies

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

Open access

Fong, Peter C., Boss, David S., Yap, Timothy A., Tutt, Andrew, Wu, Peijun, Mergui-Roelvink, Marja, Mortimer, Peter, Swaisland, Helen, Lau, Alan, O'Connor, Mark J., Ashworth, Alan, Carmichael, James, Kaye, Stan B., Schellens, Jan H.M., de Bono, Johann S.·2009·New England Journal of Medicine

DOI 10.1056/nejmoa0900212

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) is a potential synthetic lethal therapeutic strategy for the treatment of cancers with specific DNA-repair defects, including those arising in carriers of a BRCA1 or BRCA2 mutation. We conducted a clinical evaluation in humans of olaparib (AZD2281), a novel, potent, orally active PARP inhibitor. METHODS: This was a phase 1 trial that included the analysis of pharmacokinetic and pharmacodynamic characteristics of olaparib. Selection was aimed at having a study population enriched in carriers of a BRCA1 or BRCA2 mutation. RESULTS: We enrolled and treated 60 patients; 22 were carriers of a BRCA1 or BRCA2 mutation and 1 had a strong family history of BRCA-associated cancer but declined to undergo mutational testing. The olaparib dose and schedule were increased from 10 mg daily for 2 of every 3 weeks to 600 mg twice daily continuously. Reversible dose-limiting toxicity was seen in one of eight patients receiving 400 mg twice daily (grade 3 mood alteration and fatigue) and two of five patients receiving 600 mg twice daily (grade 4 thrombocytopenia and grade 3 somnolence). This led us to enroll another cohort, consisting only of carriers of a BRCA1 or BRCA2 mutation, to receive olaparib at a dose of 200 mg twice daily. Other adverse effects included mild gastrointestinal symptoms. There was no obvious increase in adverse effects seen in the mutation carriers. Pharmacokinetic data indicated rapid absorption and elimination; pharmacodynamic studies confirmed PARP inhibition in surrogate samples (of peripheral-blood mononuclear cells and plucked eyebrow-hair follicles) and tumor tissue. Objective antitumor activity was reported only in mutation carriers, all of whom had ovarian, breast, or prostate cancer and had received multiple treatment regimens. CONCLUSIONS: Olaparib has few of the adverse effects of conventional chemotherapy, inhibits PARP, and has antitumor activity in cancer associated with the BRCA1 or BRCA2 mutation. (ClinicalTrials.gov number, NCT00516373.)

Integrity signals

Registry

Crossref · 10.1056/nejmoa0900212

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Self-citation
Instability and decay of the primary structure of DNA
Lindahl, T. (1993) · Nature · doi:10.1038/362709a0 · Cited by 5,679
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Genome maintenance mechanisms for preventing cancer
Hoeijmakers, J. H. J. (2001) · Nature · doi:10.1038/35077232 · Cited by 3,939
Hallmarks of 'BRCAness' in sporadic cancers
Turner, N. C., Tutt, A. N. J., & Ashworth, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1457 · Cited by 1,690
Self-citation
The PARP superfamily
Amé, J., Spenlehauer, C., & de MURCIA, G. (2004) · BioEssays · doi:10.1002/bies.20085 · Cited by 1,463
The Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1691 · Cited by 1,405
Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition
McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O’Connor, M. J., Tutt, A. N. J., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,311
Self-citation
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086

Show all 30 references

Research works printed but not linked: 1

10.1042/BST0290655 · DOI

Sorted by citations

Items 901–1,000 of 1,012

Fanconi anemia pathway as a prospective target for cancer intervention
Liu, W., Palovcak, A., Li, F., Zafar, A., Yuan, F., & Zhang, Y. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00401-7 · Cited by 71
The Impact of m6A RNA Modification in Therapy Resistance of Cancer: Implication in Chemotherapy, Radiotherapy, and Immunotherapy
Shriwas, O., Mohapatra, P., Mohanty, S., & Dash, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.612337 · Cited by 68
BRCA-mutant pancreatic ductal adenocarcinoma
Lai, E., Ziranu, P., Spanu, D., Dubois, M., Pretta, A., Tolu, S., Camera, S., Liscia, N., Mariani, S., Persano, M., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01469-9 · Cited by 71
PARP mediated DNA damage response, genomic stability and immune responses
Zong, C., Zhu, T., He, J., Huang, R., Jia, R., & Shen, J. (2021) · International Journal of Cancer · doi:10.1002/ijc.33918 · Cited by 70
Widespread genetic epistasis among cancer genes
Wang, X., Fu, A. Q., McNerney, M. E., & White, K. P. (2014) · Nature Communications · doi:10.1038/ncomms5828 · Cited by 67
PARP-1 regulates epithelial-mesenchymal transition (EMT) in prostate tumorigenesis
Pu, H., Horbinski, C., Hensley, P. J., Matuszak, E. A., Atkinson, T. H., & Kyprianou, N. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu183 · Cited by 71
Inhibition of ATM kinase activity does not phenocopy ATM protein disruption
Choi, S., Gamper, A. M., White, J. S., & Bakkenist, C. J. (2010) · Cell Cycle · doi:10.4161/cc.9.20.13471 · Cited by 68
Synthesis of Mono-ADP-Ribosylated Oligopeptides Using Ribosylated Amino Acid Building Blocks
van Noort, G. J. V. D. H., van der Horst, M. G., Overkleeft, H. S., van der Marel, G. A., & Filippov, D. V. (2010) · Journal of the American Chemical Society · doi:10.1021/ja910940q · Cited by 67
Taking on Challenging Targets: Making MYC Druggable
Horiuchi, D., Anderton, B. N., & Goga, A. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.e497 · Cited by 67
Personalized therapies in the cancer "omics" era
Ocaña, A., & Pandiella, A. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-202 · Cited by 68
BRCA Mutation Testing in Determining Breast Cancer Therapy
Smith, K. L., & Isaacs, C. J. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e318238f579 · Cited by 67
Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials
Yuan, B., Ye, N., Song, S.-S., Wang, Y.-T., Song, Z., Chen, H., Chen, C.-H., Huan, X., Wang, Y.-Q., Su, Y., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.11.010 · Cited by 67
Genomic analysis of DNA repair genes and androgen signaling in prostate cancer
Jividen, K., Kedzierska, K., Yang, C., Szlachta, K. A., Ratan, A., & Paschal, B. M. (2018) · BMC Cancer · doi:10.1186/s12885-018-4848-x · Cited by 68
Gene expression profiling of formalin‐fixed, paraffin‐embedded familial breast tumours using the whole genome‐DASL assay
Waddell, N., Cocciardi, S., Johnson, J., Healey, S. C., Marsh, A. J., Riley, J., Silva, L. M. D., Vargas, A. C., Reid, L., Simpson, P. T., et al. (2010) · The Journal of Pathology · doi:10.1002/path.2728 · Cited by 66
Preclinical Characterization of AZD9574, a Blood–Brain Barrier Penetrant Inhibitor of PARP1
Staniszewska, A. D., Pilger, D., Gill, S. J., Jamal, K., Bohin, N., Guzzetti, S., Gordon, J. A., Hamm, G. R., Mundin, G., Illuzzi, G., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2094 · Cited by 66
Self-citation
BRCA1 16 years later: nuclear import and export processes
Thompson, M. E. (2010) · FEBS Journal · doi:10.1111/j.1742-4658.2010.07733.x · Cited by 66
Aurora‐A expressing tumour cells are deficient for homology‐directed DNA double strand‐break repair and sensitive to PARP inhibition
Sourisseau, T., Maniotis, D., McCarthy, A., Tang, C., Lord, C. J., Ashworth, A., & Linardopoulos, S. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000068 · Cited by 66
Self-citation
Personalized therapy in endometrial cancer: Challenges and opportunities
Westin, S. N., & Broaddus, R. R. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.13.1.18438 · Cited by 66
Structural biology of the writers, readers, and erasers in mono- and poly(ADP-ribose) mediated signaling
Karlberg, T., Langelier, M.-F., Pascal, J. M., & Schuler, H. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.02.002 · Cited by 68
BRCA1 in the DNA damage response and at telomeres
Rosen, E. M. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00085 · Cited by 68
PARP Inhibition Suppresses Growth of EGFR-Mutant Cancers by Targeting Nuclear PKM2
Li, N., Feng, L., Liu, H., Wang, J., Kasembeli, M. M., Tran, M. K., Tweardy, D. J., Lin, S. H., & Chen, J. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.070 · Cited by 66
DNA damage repair in breast cancer and its therapeutic implications
Ali, R., Rakha, E. A., Madhusudan, S., & Bryant, H. E. (2016) · Pathology · doi:10.1016/j.pathol.2016.11.002 · Cited by 66
Bi‐allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer
Mutter, R. W., Riaz, N., Ng, C. K. Y., Delsite, R., Piscuoglio, S., Edelweiss, M., Martelotto, L. G., Sakr, R. A., King, T. A., Giri, D. D., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4890 · Cited by 68
Targeting the DNA damage response in oncology
Basu, B., Yap, T. A., Molife, L. R., & Bono, J. S. D. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835280c6 · Cited by 68
Self-citation
Synergistic Effect of Olaparib with Combination of Cisplatin on PTEN -Deficient Lung Cancer Cells
Minami, D., Takigawa, N., Takeda, H., Takata, M., Ochi, N., Ichihara, E., Hisamoto, A., Hotta, K., Tanimoto, M., & Kiura, K. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0401 · Cited by 65
Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 Mutation
Caulfield, S. E., Christine C. Davis, P., & Byers, K. (2019) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2019.10.2.6 · Cited by 65
BRCA1 Mutations in Cancer: Coordinating Deficiencies in Homologous Recombination with Tumorigenesis
Krais, J. J., & Johnson, N. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1830 · Cited by 66
Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells
Dominici, C., Sgarioto, N., Yu, Z., Sesma-Sanz, L., Masson, J., Richard, S., & Raynal, N. J. ‐. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01037-1 · Cited by 66
RETRACTED: Transcriptome-scale RNA-targeting CRISPR screens reveal essential lncRNAs in human cells
Liang, W.-W., Müller, S., Hart, S. K., Wessels, H., Méndez‐Mancilla, A., Sookdeo, A., Choi, O., Caragine, C. M., Corman, A., Lu, L., et al. (2024) · Cell · doi:10.1016/j.cell.2024.10.021 · Cited by 68
Retracted
Prognostic and Therapeutic Implications of Distinct Kinase Expression Patterns in Different Subtypes of Breast Cancer
Bianchini, G., Iwamoto, T., Qi, Y., Coutant, C., Shiang, C. Y., Wang, B., Santarpia, L., Valero, V., Hortobágyi, G. N., Symmans, W. F., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1039 · Cited by 65
Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers
Vollebergh, M. A., Jonkers, J., & Linn, S. C. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0809-0 · Cited by 68
Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells
Miyasaka, A., Oda, K., Ikeda, Y., Wada‐Hiraike, O., Kashiyama, T., Enomoto, A., Hosoya, N., Koso, T., Fukuda, T., Inaba, K., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-179 · Cited by 65
Poly(ADP-Ribose) Polymerase 1 (PARP1) Overexpression in Human Breast Cancer Stem Cells and Resistance to Olaparib
Gilabert, M., Launay, S., Ginestier, C., Bertucci, F., Audebert, S., Pophillat, M., Toiron, Y., Baudelet, É., Finetti, P., Noguchi, T., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104302 · Cited by 65
PARP-1 Regulates Resistance of Pancreatic Cancer to TRAIL Therapy
Yuan, K., Sun, Y., Zhou, T., McDonald, J. M., & Chen, Y. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0516 · Cited by 67
Novel strategies for reversing platinum resistance
Shahzad, M. M. K., Lopez‐Berestein, G., & Sood, A. K. (2009) · Drug Resistance Updates · doi:10.1016/j.drup.2009.09.001 · Cited by 68
The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines
Davidson, D. L., Wang, Y., Aloyz, R. S., & Panasci, L. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9886-7 · Cited by 69
Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma
Dolman, M. E. M., Poon, E., Ebus, M. E., den Hartog, I. J. M., van Noesel, C. J. M., Jamin, Y., Hallsworth, A., Robinson, S. P., Petrie, K. R., Sparidans, R. W., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0313 · Cited by 66
'BRCAness' and its implications for platinum action in gynecologic cancer.
Muggia, F. M., & Safra, T. (2014) · PubMed · Cited by 65
Poly(ADP-ribose) Polymerase-1 Is a Nuclear Epigenetic Regulator of Mitochondrial DNA Repair and Transcription
Lapucci, A., Pittelli, M. G., Rapizzi, E., Felici, R., Moroni, F., & Chiarugi, A. (2011) · Molecular Pharmacology · doi:10.1124/mol.110.070110 · Cited by 65
Breaking the DNA damage response to improve cervical cancer treatment
Wieringa, H. W., van der Zee, A. G. J., de Vries, E. G. E., & van Vugt, M. A. T. M. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.11.008 · Cited by 66
A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia
Gojo, I., Beumer, J. H., Pratz, K. W., McDevitt, M. A., Baer, M. R., Blackford, A. L., Smith, B. D., Gore, S. D., Carraway, H. E., Showel, M. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0984 · Cited by 65
N-methyl-2-pyridone-5-carboxamide (2PY)—Major Metabolite of Nicotinamide: An Update on an Old Uremic Toxin
Lenglet, A., Liabeuf, S., Bodeau, S., Louvet, L., Mary, A., Boullier, A., Lemaire-Hurtel, A., Jonet, A., Sonnet, P., Kamel, S., et al. (2016) · Toxins · doi:10.3390/toxins8110339 · Cited by 65
The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies
Rimar, K. J., Tran, P. T., Matulewicz, R. S., Hussain, M., & Meeks, J. J. (2017) · Cancer · doi:10.1002/cncr.30631 · Cited by 66
H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer
Mazzucchelli, S., Truffi, M., Baccarini, F., Beretta, M., Sorrentino, L., Bellini, M., Rizzuto, M. A., Ottria, R., Ravelli, A., Ciuffreda, P., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-07617-7 · Cited by 65
Synthesis and biological activity of structurally diverse phthalazine derivatives: A systematic review
Sangshetti, J. N., Pathan, S. K., Patil, R. B., Ansari, S. A., Chhajed, S. S., Arote, R. B., & Shinde, D. B. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.07.050 · Cited by 65
Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer
Yamashita, N., Tokunaga, E., Kitao, H., Hitchins, M. P., Inoue, Y., Tanaka, K., Hisamatsu, Y., Taketani, K., Akiyoshi, S., Okada, S., et al. (2015) · Clinical Breast Cancer · doi:10.1016/j.clbc.2015.06.009 · Cited by 65
DNA repair mechanisms protect our genome from carcinogenesis
Moraes, M. C. S. (2012) · Frontiers in Bioscience · doi:10.2741/3992 · Cited by 64
A Comparative Genomic Approach for Identifying Synthetic Lethal Interactions in Human Cancer
Deshpande, R., Asiedu, M. K., Klebig, M., Sutor, S., Kuzmin, E., Nelson, J., Piotrowski, J., Ho Shin, S., Yoshida, M., Costanzo, M., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3956 · Cited by 64
A Blueprint for Advancing Genetics-Based Cancer Therapy
Sellers, W. R. (2011) · Cell · doi:10.1016/j.cell.2011.09.016 · Cited by 65
Poly(ADP-ribose) polymerase activity and inhibition in cancer
Dulaney, C. R., Marcrom, S., Stanley, J. A., & Yang, E. S.-H. (2017) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2017.01.007 · Cited by 66
PARP Inhibitors in Prostate Cancer–the Preclinical Rationale and Current Clinical Development
Virtanen, V., Paunu, K., Ahlskog, J. K., Várnai, R., Sipeky, C., & Sundvall, M. (2019) · Genes · doi:10.3390/genes10080565 · Cited by 67
Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
de Haan, R., van den Heuvel, M. M., van Diessen, J., Peulen, H. M. U., van Werkhoven, E. D., de Langen, A. J., Lalezari, F., Pluim, D., Verwijs-Janssen, M., Vens, C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2551 · Cited by 64
Self-citation
Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies
Russo, A. D., Incorvaia, L., Capoluongo, E., Tagliaferri, P., Gori, S., Cortesi, L., Genuardi, M., Turchetti, D., Giorgi, U. D., Maïo, M. D., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100459 · Cited by 65
Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL)
Zenz, T., Fröhling, S., Mertens, D., Döhner, H., & Stilgenbauer, S. (2010) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2009.12.003 · Cited by 64
Androgen receptor expression predicts different clinical outcomes for breast cancer patients stratified by hormone receptor status
Jiang, H.-S., Kuang, X.-Y., Sun, W.-L., Xu, Y., Zheng, Y.-Z., Liu, Y., Lang, G., Qiao, F., Hu, X., & Shao, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.9778 · Cited by 64
Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care
Graffeo, R., Livraghi, L., Pagani, O., Goldhirsch, A., Partridge, A. H., & Garber, J. E. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-4003-9 · Cited by 69
Olaparib for the treatment of breast cancer
Griguolo, G., Dieci, M. V., Guarneri, V., & Conte, P. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1458613 · Cited by 66
Degradation of 5hmC-marked stalled replication forks by APE1 causes genomic instability
Kharat, S. S., Ding, X., Swaminathan, D., Suresh, A., Singh, M. P., Sengodan, S. K., Burkett, S. S., Marks, H., Pamala, C., He, Y., et al. (2020) · Science Signaling · doi:10.1126/scisignal.aba8091 · Cited by 64
PARP Inhibitors in Small-Cell Lung Cancer: Rational Combinations to Improve Responses
Knelson, E. H., Patel, S. A., & Sands, J. M. (2021) · Cancers · doi:10.3390/cancers13040727 · Cited by 65
Melanoma: A model for testing new agents in combination therapies
Ascierto, P. A., STREICHER, H. Z., & Sznol, M. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-38 · Cited by 63
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Morgan, R. D., Clamp, A. R., Evans, D. G., Edmondson, R. J., & Jayson, G. C. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3532-9 · Cited by 66
Analysis of mutational signatures with yet another package for signature analysis
Hübschmann, D., Jopp‐Saile, L., Andresen, C., Krämer, S., Gu, Z., Heilig, C. E., Kreutzfeldt, S., Teleanu, V., Fröhling, S., Eils, R., et al. (2020) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22918 · Cited by 67
MUC4 Overexpression Augments Cell Migration and Metastasis through EGFR Family Proteins in Triple Negative Breast Cancer Cells
Mukhopadhyay, P., Lakshmanan, I., Ponnusamy, M. P., Chakraborty, S., Jain, M., Pai, P., Smith, L. M., Lele, S. M., & Batra, S. K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054455 · Cited by 63
Molecular Pathways: Targeting ETS Gene Fusions in Cancer
Feng, F. Y.-C., Brenner, J. C., Hussain, M., & Chinnaiyan, A. M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0275 · Cited by 63
PARP inhibitor, olaparib ameliorates acute lung and kidney injury upon intratracheal administration of LPS in mice
Kapoor, K., Singla, E., Sahu, B., & Naura, A. S. (2014) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-014-2271-4 · Cited by 63
BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations
Holstege, H. H., Horlings, H. M., Velds, A., Langerød, A., Børresen‐Dale, A., van de Vijver, M. J., Nederlof, P. M., & Jonkers, J. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-654 · Cited by 63
Enhancement of Synthetic Lethality via Combinations of ABT-888, a PARP Inhibitor, and Carboplatin In Vitro and In Vivo Using BRCA1 and BRCA2 Isogenic Models
Clark, C. C., Weitzel, J. N., & O'Connor, T. R. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0597 · Cited by 66
The pathogenesis, diagnosis and management of congenital dyserythropoietic anaemia type I
Roy, N. B. A., & Babbs, C. (2019) · British Journal of Haematology · doi:10.1111/bjh.15817 · Cited by 63
Molecular prescreening to select patient population in early clinical trials
Rodon, J. A., Saura, C., Dienstmann, R., Vivancos, A. P., y Cajal, S. R., Baselga, J. M., & Tabernero, J. M. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.48 · Cited by 62
Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene
Ghafoor, A., Mian, I., Wagner, C., Mallory, Y., Agra, M., Morrow, B., Wei, J. S., Khan, J. I., Thomas, A., Sengupta, M., et al. (2021) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2021.100231 · Cited by 62
Nimbolide targets RNF114 to induce the trapping of PARP1 and synthetic lethality in BRCA -mutated cancer
Li, P., Zhen, Y., Kim, C., Liu, Z., Hao, J., Deng, H., Deng, H., Zhou, M., Wang, X., Qin, T., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg7752 · Cited by 64
BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib
Faraoni, I., Compagnone, M., Lavorgna, S., Angelini, D. F., Cencioni, M. T., Piras, E., Panetta, P., Ottone, T., Dolci, S., Venditti, A., et al. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.12.001 · Cited by 65
The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition
XIA, Q., Cai, Y., Peng, R., Wu, G., Shi, Y., & Jiang, W. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2240 · Cited by 62
BRCA Gene Structure and Function in Tumor Suppression
Murphy, C. G., & Moynahan, M. E. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181cf0204 · Cited by 63
PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells
Booth, L. A., Cruickshanks, N. A., Ridder, T. S., Dai, Y., Grant, S., & Dent, P. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.24424 · Cited by 62
Genetic Testing by Cancer Site
Weissman, S. M., Weiss, S. M., & Newlin, A. C. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e31826246c2 · Cited by 62
Breast cancer genomes — form and function
Korkola, J. E., & Gray, J. W. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.11.005 · Cited by 68
A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population
Belanger, M. H., Dolman, L. I., Arcand, S. L., Shen, Z. Z., Chong, G., Mes‐Masson, A., Provencher, D. M., & Tonin, P. N. (2015) · Journal of Ovarian Research · doi:10.1186/s13048-015-0124-8 · Cited by 62
The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies
Reinbolt, R. E., & Hays, J. L. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00237 · Cited by 62
PARP Inhibitors in Prostate Cancer
Geethakumari, P. R., Schiewer, M. J., Knudsen, K. E., & Kelly, W. K. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0480-2 · Cited by 64
PARP‐1 regulates DNA repair factor availability
Schiewer, M. J., Mandigo, A. C., Gordon, N., Huang, F., Gaur, S., de Leeuw, R., Zhao, S. G., Evans, J. R., Han, S., Parsons, T., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708816 · Cited by 63
Personalizing Therapy for Ovarian Cancer: BRCAness and Beyond
Bast, R. C., & Mills, G. B. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.5791 · Cited by 62
Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the ovarian cancer association consortium (OCAC)
Bolton, K. L., Ganda, C., Berchuck, A., Pharaoh, P. D. P., & Gayther, S. A. (2012) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2011.02509.x · Cited by 61
Shaping the BRCAness mutational landscape by alternative double-strand break repair, replication stress and mitotic aberrancies
Stok, C., Kok, Y. P., van den Tempel, N., & van Vugt, M. A. T. M. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab151 · Cited by 67
Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols
Cottrell, T. R., Lotze, M. T., Ali, A. M., Bifulco, C. B., Capitini, C. M., Chow, L. Q. M., Cillo, A. R., Collyar, D. E., Cope, L., Deutsch, J. S., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010928 · Cited by 65
Targeting abnormal DNA double strand break repair in cancer
Rassool, F. V., & Tomkinson, A. E. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0493-5 · Cited by 62
Novel therapeutic approaches to the treatment of metastatic breast cancer
Fernández, Y., Cueva, J. F., Palomo, A. G., Ramos, M., Juan, A. D., Calvo, L., García-Mata, J., García‐Teijido, P., Peláez, I., & García‐Estévez, L. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.10.001 · Cited by 61
Molecular Pathways: Targeting Resistance in the Androgen Receptor for Therapeutic Benefit
Mostaghel, E. A., Plymate, S. R., & Montgomery, B. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3601 · Cited by 63
Advances in Small-Cell Lung Cancer (SCLC) Translational ResearchPreprint
Drapkin, B. J., & Rudin, C. M. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a038240 · Cited by 63
Vitamin D/vitamin D receptor axis regulates DNA repair during oncogene-induced senescence
Graziano, S., Johnston, R., Deng, O., Zhang, J., & Gonzalo, S. (2016) · Oncogene · doi:10.1038/onc.2016.77 · Cited by 60
NAD+ metabolism as a target for metabolic health: have we found the silver bullet?
Connell, N. J., Houtkooper, R. H., & Schrauwen, P. (2019) · Diabetologia · doi:10.1007/s00125-019-4831-3 · Cited by 60
Single cell resolution in vivo imaging of DNA damage following PARP inhibition
Yang, K. S., Köhler, R. H., Landon, M., Giedt, R. J., & Weissleder, R. (2015) · Scientific Reports · doi:10.1038/srep10129 · Cited by 61
Poly(ADP-Ribose) Polymerase-1 Inhibition: Preclinical and Clinical Development of Synthetic Lethality
Leung, M., Rosen, D. B., Fields, S. Z., Cesano, A., & Budman, D. R. (2011) · Molecular Medicine · doi:10.2119/molmed.2010.00240 · Cited by 60
Poly(ADP-ribose) Polymerase Inhibitors Sensitize Cancer Cells to Death Receptor-mediated Apoptosis by Enhancing Death Receptor Expression
Meng, X. W., Koh, B. D., Zhang, J., Flatten, K. S., Schneider, P. A., Billadeau, D. D., Hess, A. D., Smith, B. D., Karp, J. E., & Kaufmann, S. H. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.549220 · Cited by 63
Molecular targets and targeted therapeutics in endometrial cancer
Weigelt, B., & Banerjee, S. N. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328354e585 · Cited by 60
New molecular targets in radiotherapy: DNA damage signalling and repair in targeted and non-targeted cells
Burdak‐Rothkamm, S., & Prise, K. M. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.09.068 · Cited by 60
BRCAness Profile of Sporadic Ovarian Cancer Predicts Disease Recurrence
Wysham, W. Z., Mhawech-Fauceglia, P. Y., Li, H., Hays, L. E., Syriac, S., Skrepnik, T., Wright, J., Pande, N. T., Hoatlin, M. E., & Pejovic, T. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030042 · Cited by 60
PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles
Ellisen, L. W. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.047 · Cited by 60
Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells
Choi, Y. E., Battelli, C., Watson, J., Liu, J. F., Curtis, J. D., Morse, A., Matulonis, U. A., Chowdhury, D., & Konstantinopoulos, P. A. (2014) · Oncotarget · doi:10.18632/oncotarget.1929 · Cited by 60
PARP expression in germ cell tumours
Mego, M., Čierna, Z., Světlovská, D., Macák, D., Macháleková, K., Miskovska, V., Chovanec, M., Usakova, V., Obertová, J., Babál, P., et al. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-201088 · Cited by 61

Authors: Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., Ashworth, A., Carmichael, J., Kaye, S. B., Schellens, J. H. M., & de Bono, J. S.
Affiliations: National Health Service (GB)
The Netherlands Cancer Institute (NL)
Institute of Cancer Research (GB)
AstraZeneca (United Kingdom) (GB)
Utrecht University (NL)
ORCID: Fong, Peter C.
Yap, Timothy A.
Tutt, Andrew
Wu, Peijun
Mortimer, Peter
Lau, Alan
Ashworth, Alan
Kaye, Stan B.
Schellens, Jan H.M.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2009-07-09
Volume: 361
Issue: 2
Pages: 123-134
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa0900212
OpenAlex: W2171972386
Cited by: 3,634
References: 30
Citations by year: 2026: 79 · 2025: 113 · 2024: 126 · 2023: 152 · 2022: 188 · 2021: 189 · 2020: 173 · 2019: 195 · 2018: 190 · 2017: 214 · 2016: 249 · 2015: 252 · 2014: 244 · 2013: 247 · 2012: 285
FWCI: 170.91
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Research Portal (King's College London) (submittedVersion)
Funders: AstraZeneca
Royal Marsden NHS Foundation Trust
NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
Cancer Research UK (A8363)
National Institute for Health and Care Research
Topics: Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords: olaparib, PARP inhibitors, BRCA1 mutation carriers, BRCA2 mutation carriers, synthetic lethality, DNA repair deficiency, ovarian cancer, breast cancer, prostate cancer, pharmacokinetics, pharmacodynamics, dose-limiting toxicity, thrombocytopenia, anticancer activity
MeSH terms: Poly(ADP-ribose) Polymerase Inhibitors, Adult, Aged, Aged, 80 and over, Dose-Response Relationship, Drug, Female, Heterozygote, Humans, Male, Middle Aged, Neoplasms, Phthalazines, Piperazines, Drug Design, Germ-Line Mutation, Genes, BRCA1, Genes, BRCA2, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks